| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2017PLoSO..1269830D |
| P356 | DOI | 10.1371/JOURNAL.PONE.0169830 |
| P932 | PMC publication ID | 5321277 |
| P698 | PubMed publication ID | 28225768 |
| P50 | author | Pier Luigi Meroni | Q38544871 |
| Barbara Bottazzi | Q42306567 | ||
| Milada Cvancarova Småstuen | Q42539508 | ||
| P2093 | author name string | Stefan Agewall | |
| Torstein Lyberg | |||
| Ivana Hollan | |||
| Roberto Leone | |||
| Jon Elling Whist | |||
| Gia Deyab | |||
| Gunnbjorg Hjeltnes | |||
| Ingrid Hokstad | |||
| P2860 | cites work | Six persistent research misconceptions | Q24289462 |
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Inflammation in atherosclerosis | Q29547428 | ||
| American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis | Q30829836 | ||
| An integrated view of humoral innate immunity: pentraxins as a paradigm | Q34020449 | ||
| Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria | Q34055060 | ||
| PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation | Q34106947 | ||
| Production of the long pentraxin PTX3 in advanced atherosclerotic plaques | Q34128059 | ||
| Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, ARMY and ARFY Studies | Q34154838 | ||
| Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis | Q34579101 | ||
| Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. | Q34719466 | ||
| Clinical application of C-reactive protein for cardiovascular disease detection and prevention | Q35054464 | ||
| Pentraxin 3(PTX 3): an endogenous modulator of the inflammatory response | Q35915482 | ||
| Association of Pentraxin 3 with Autoimmune Diseases: A Systematic Review and Meta-Analysis | Q36038626 | ||
| The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps | Q36229261 | ||
| Cardiovascular co-morbidity in rheumatic diseases | Q36835851 | ||
| Increased long-term expression of pentraxin 3 in irradiated human arteries and veins compared to internal controls from free tissue transfers | Q37361154 | ||
| The time profile of Pentraxin 3 in patients with acute ST-elevation myocardial infarction and stable angina pectoris undergoing percutaneous coronary intervention. | Q37668815 | ||
| Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases | Q37778556 | ||
| Anti-TNF-α Agents in the Treatment of Immune-Mediated Inflammatory Diseases: Mechanisms of Action and Pitfalls | Q37810960 | ||
| 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis | Q37871699 | ||
| Cardiovascular comorbidity in rheumatic diseases | Q38568465 | ||
| Pentraxins and Collectins: Friend or Foe during Pathogen Invasion? | Q38611424 | ||
| Pentraxin 3 is a marker of early joint inflammation in patients with juvenile idiopathic arthritis. | Q39167651 | ||
| Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease | Q39650370 | ||
| Increased levels of serum pentraxin 3, a novel cardiovascular biomarker, in patients with inflammatory rheumatic disease | Q43099986 | ||
| Levels of pentraxin 3 and relationship with disease activity in patients with ankylosing spondylitis | Q44007081 | ||
| Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells | Q44985116 | ||
| Pentraxin-3 as a marker of disease activity in Takayasu arteritis | Q45208023 | ||
| Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations | Q46071688 | ||
| Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. | Q50701991 | ||
| Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. | Q51630649 | ||
| Long pentraxin 3: a marker of inflammation in untreated psoriatic patients. | Q51936774 | ||
| Reproducibility of different methods to measure the endothelial function. | Q53096870 | ||
| Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. | Q53510759 | ||
| Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity. | Q53547582 | ||
| Spondyloarthritis: Is methotrexate effective in psoriatic arthritis? | Q54162420 | ||
| Deficiency of the Long Pentraxin PTX3 Promotes Vascular Inflammation and Atherosclerosis | Q56942567 | ||
| Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction | Q56942653 | ||
| Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA) | Q56943278 | ||
| Serological markers in psoriatic arthritis: promising tools | Q61649487 | ||
| Development of anti-TNF therapy for rheumatoid arthritis | Q74187188 | ||
| Anti-CCP and RF IgM: predictors of impaired endothelial function in rheumatoid arthritis patients | Q82852725 | ||
| Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease | Q83192731 | ||
| The levels of serum pentraxin3, CRP, fetuin-A, and insulin in patients with psoriasis | Q86222431 | ||
| Levels of serum pentraxin 3, IL-6, fetuin A and insulin in patients with rheumatoid arthritis | Q89383407 | ||
| Psoriatic arthritis | Q93745377 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| psoriatic arthritis | Q511097 | ||
| P304 | page(s) | e0169830 | |
| P577 | publication date | 2017-02-22 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis | |
| P478 | volume | 12 |
| Q42682318 | Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis |
| Q55447799 | Study on Association of Pentraxin 3 and Diabetic Nephropathy in a Rat Model. |
| Q92121586 | Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study |
Search more.